SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Registry sponsor category
Industry
- Other names
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Company name
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (13)
- A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
- Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
- Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
- Individual Patient Compassionate Use of Mirdametinib
- Individual Patient Compassionate Use of Nirogacestat
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
- Mirdametinib + BGB-3245 in Advanced Solid Tumors
- Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
- Nirogacestat in Ovarian Granulosa Cell Tumors
- Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
- SW-682 in Advanced Solid Tumors
- To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants
- To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants